The authors were able to identify multiple factors that conferred resistance to the different drugs; however, they focused their study on KEAP1, as it was found to modulate sensitivity to EGFR, ALK, BRAF or MEK (MAPKK/ERK) inhibition in lung cancer cell lines with a range of mutational backgrounds, which included EGFR, ALK, BRAF, KRAS or NRAS mutations. This evidence concerns the gene BRAF and lung carcinoma.